Clinical trials: Patients With Type 2 Diabetes
Diabetes Mellitus Type 2
A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy
This randomized, open-label, parallel arm study will compare the safety, tolerability and effect on glycemic control of taspoglutide versus insulin glargine in insulin-naïve patients with type 2 diabetes mellitus inadequately…
- Trial name
- NCT01051011
- Testing
- insulin glargine, metformin, taspoglutide
- Where
- 56 sites in China, Hong Kong and 5 more
- Volunteers
- 370 people
- Sponsor
- Hoffmann-La Roche
Type 1 Diabetes, Type 2 Diabetes
Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device
The primary objective of this study is to compare patient preference of the h-Patch as delivery device for insulin lispro compared with either an insulin pen or needle and syringe in patients with diabetes, either Type 1 or Type…
- Trial name
- NCT00453934
- Testing
- h-Patch
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Valeritas, Inc.
Type 2 Diabetes
Observational Study of Effectiveness and Tolerability of Gliclazide MR 60mg in Diabetic Patients Fasting During RAMADAN
The purpose of this observational study is to assess effectiveness and tolerability of gliclazide MR 60mg during RAMADAN in a real world setting in 9 countries from Asia Pacific and Middle East/North Africa
- Trial name
- DIA-RAMADAN (NCT04132934)
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Servier Affaires Médicales
Type 2 Diabetes Mellitus
POLUS: Description of the Effectiveness and Tolerability of Luseogliflozin in Patients With Type 2 Diabetes.
In this non-interventional study, the effectiveness and tolerability of Lusefi® in adult patients with type 2 diabetes will be evaluated.
- Trial name
- POLUS (NCT07433192)
- Where
- Russia
- Volunteers
- 300 people
- Sponsor
- Servier Russia
Type 2 Diabetes Mellitus - Poor Control
A Study of CJC-1134-PC Injection in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues
This study is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Designed to Evaluate the Efficacy and Safety of CJC-1134-PC Injection Administered Once A Week in Patients with Type 2 Diabetes…
- Trial name
- NCT07057271
- Testing
- CJC-1134-PC Injection
- Where
- China
- Volunteers
- 464 people
- Sponsor
- Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
Type 2 Diabetes Mellitus
Randomized, Double-Blind, Placebo-Controlled, With PHX1149 in Patients With Type 2 Diabetes Mellitus
This will be a 4-week, multicenter, randomized, double-blind, parallel group, placebo-controlled, safety, tolerability, and efficacy study.
- Trial name
- NCT00530881
- Testing
- PHX1149
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Phenomix
Type 2 Diabetes
To Evaluate the Response to Glucagon During Hypoglycemia
The purpose of this study is to evaluate the response to Glucagon versus the spontaneous hormonal response to low blood sugar levels in T2DM Patients treated with AZD1656 and Metformin
- Trial name
- NCT00817271
- Testing
- AZD1656, Glucagon
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin
Primary objective: To show an improvement in HbA1c control after 4 months of treatment with insulin glargine + Oral Anti Diabetic (OAD) in patients previously uncontrolled on premixed insulin (with OAD) Secondary objective…
- Trial name
- OPTIMIZATION (NCT00693771)
- Testing
- Insulin Glargine
- Where
- China
- Volunteers
- 313 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety and efficacy of KAD-1229 as combination therapy with insulin for 16 weeks and up to 52 weeks administration in patients with type 2 Diabetes Mellitus who show inadequate…
- Trial name
- NCT02154347
- Testing
- KAD-1229, Insulin
- Where
- Japan
- Volunteers
- 178 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00039013
- Testing
- AC2993
- Where
- 129 sites in United States
- Volunteers
- 336 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Risk of Cardiovascular Events in Patients With Type 2 Diabetes Initiating Oral Antidiabetic Treatments
The purpose of this study is to compare the incidence of major cardiovascular events among patients with type 2 diabetes who are new initiators of Saxagliptin and those who are new initiators of oral anti-diabetic drugs (OADs)in…
- Trial name
- NCT01086280
- Volunteers
- 113,505 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients
The primary purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of PF-05175157 in healthy volunteers and patients with type 2 diabetes mellitus.
- Trial name
- NCT01396161
- Where
- 3 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)
The present study is designed to evaluate the efficacy and safety of fixed combination therapy of vildagliptin and metformin (25/1000 mg bid) in patients with type 2 diabetes inadequately controlled with prior metformin…
- Trial name
- NCT00728351
- Testing
- vildagliptin + metformin, metformin
- Where
- 63 sites in United States, France and 3 more
- Volunteers
- 317 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of a fixed combination of vildagliptin and metformin in lowering blood glucose in patients with type 2 diabetes
- Trial name
- NCT00382096
- Testing
- Vildagliptin, Metformin, Vildagliptin + Metformin
- Where
- 2 sites in United States, Germany
- Volunteers
- 1,179 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus Type 2
A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.
This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO5095932 in adult patients with type 2 diabetes mellitus.
- Trial name
- NCT01017302
- Testing
- RO5095932
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Diabetes Mellitus, Type 2
Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin
This study is conducted in Europe. An observational study evaluating the blood glucose control in patients using a modern insulin: NovoRapid®, NovoMix® 30 or Levemir® for treatment of Type 2 diabetes mellitus in Czech Republic.
- Trial name
- NCT00670722
- Testing
- insulin aspart, insulin detemir, biphasic insulin aspart 30
- Where
- Czechia
- Volunteers
- 6,500 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Chronic Kidney Disease
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys.
- Trial name
- REMODEL (NCT04865770)
- Testing
- Semaglutide
- Where
- 49 sites in United States, Canada and 6 more
- Volunteers
- 106 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Hypertension
A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension
- Trial name
- NCT05970237
- Where
- South Korea
- Volunteers
- 9,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes Mellitus, Type 2
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India
The main purpose of this study is to evaluate safety of dulaglutide in participants with type 2 diabetes mellitus in India.
- Trial name
- NCT05659537
- Testing
- Dulaglutide
- Where
- 7 sites in India
- Volunteers
- 212 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Pilot Study of ONO-5129 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of ONO-5129 in patients with type 2 diabetes mellitus.
- Trial name
- NCT00335712
- Testing
- ONO-5129
- Where
- 2 sites in Japan
- Volunteers
- 81 people
- Sponsor
- Ono Pharma USA Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.